

Alakananda Basu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3188170/publications.pdf>

Version: 2024-02-01

74
papers

9,011
citations

172457

29
h-index

98798

67
g-index

74
all docs

74
docs citations

74
times ranked

18003
citing authors

#	ARTICLE	IF	CITATIONS
1	The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy. , 2022, 230, 107943.		79
2	Akt Isoforms: A Family Affair in Breast Cancer. Cancers, 2021, 13, 3445.	3.7	31
3	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50,662 1,430	9.1	4,701
4	Regulation of Autophagy by Protein Kinase C- μ in Breast Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 4247.	4.1	14
5	Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 1199.	4.1	52
6	The Emerging Roles of mTORC1 in Macromanaging Autophagy. Cancers, 2019, 11, 1422.	3.7	180
7	The Enigmatic Protein Kinase C-eta. Cancers, 2019, 11, 214.	3.7	12
8	Differential effects of protein kinase C-eta on apoptosis versus senescence. Cellular Signalling, 2019, 55, 1-7.	3.6	6
9	Protein kinase C-eta regulates Mcl-1 level via ERK1. Cellular Signalling, 2017, 40, 166-171.	3.6	12
10	Regulation of anti-apoptotic Bcl-2 family protein Mcl-1 by S6 kinase 2. PLoS ONE, 2017, 12, e0173854.	2.5	16
11	Emerging therapeutics for targeting Akt in cancer. Frontiers in Bioscience - Landmark, 2016, 21, 757-768.	3.0	12
12	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
13	The Multifunctional Protein Kinase C- μ in Cancer Development and Progression. Cancers, 2014, 6, 860-878.	3.7	53
14	The unique protein kinase C δ : Implications for breast cancer (Review). International Journal of Oncology, 2014, 45, 493-498.	3.3	7
15	Protein Kinase C- μ Promotes EMT in Breast Cancer. Breast Cancer: Basic and Clinical Research, 2014, 8, BCBCR.S13640.	1.1	27
16	Upregulation of PKC δ by PKC μ and PDK1 involves two distinct mechanisms and promotes breast cancer cell survival. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 4040-4045.	2.4	16
17	P300 regulates the human RLIP76 promoter activity and gene expression. Biochemical Pharmacology, 2013, 85, 1203-1211.	4.4	13
18	Autophagy in breast cancer and its implications for therapy. American Journal of Cancer Research, 2013, 3, 251-65.	1.4	42

#	ARTICLE	IF	CITATIONS
19	Novel regulation of protein kinase C δ . Biochemical and Biophysical Research Communications, 2012, 425, 836-841.	2.1	14
20	S6 Kinase 2 Promotes Breast Cancer Cell Survival via Akt. Cancer Research, 2011, 71, 2590-2599.	0.9	44
21	PKC μ paves the way for prostate cancer. Cell Cycle, 2011, 10, 378-378.	2.6	4
22	Regulation of IKK α Expression by Akt2 Isoform. Genes and Cancer, 2011, 2, 1044-1050.	1.9	5
23	Regulation of Autophagy by Kinases. Cancers, 2011, 3, 2630-2654.	3.7	158
24	PKC μ induces Bcl-2 by activating CREB. International Journal of Oncology, 2010, 36, 883-8.	3.3	10
25	Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression. Cancer Chemotherapy and Pharmacology, 2010, 66, 945-952.	2.3	16
26	NSC109268 potentiates cisplatin-induced cell death in a p53-independent manner. Journal of Molecular Signaling, 2010, 5, 4.	0.5	4
27	Cellular Responses to Cisplatin-Induced DNA Damage. Journal of Nucleic Acids, 2010, 2010, 1-16.	1.2	361
28	Two Faces of Protein Kinase C δ : The Contrasting Roles of PKC δ in Cell Survival and Cell Death. Scientific World Journal, The, 2010, 10, 2272-2284.	2.1	116
29	PKC and Resistance to Chemotherapeutic Agents. , 2010, , 409-429.		2
30	Regulation of protein kinase C δ downregulation by protein kinase C μ and mammalian target of rapamycin complex 2. Cellular Signalling, 2009, 21, 1680-1685.	3.6	10
31	Proteolytic Cleavage of p70 Ribosomal S6 Kinase by Caspase-3 during DNA Damage-Induced Apoptosis. Biochemistry, 2009, 48, 1474-1480.	2.5	24
32	Down-regulation of Caspase-2 by Rottlerin via Protein Kinase C- δ -Independent Pathway. Cancer Research, 2008, 68, 2795-2802.	0.9	34
33	Chapter 8 Manipulation of PKC Isozymes by RNA Interference and Inducible Expression of PKC Constructs. Methods in Enzymology, 2008, 446, 141-157.	1.0	2
34	Article Commentary: Molecular Targets of Breast Cancer: AKTing in Concert. Breast Cancer: Basic and Clinical Research, 2008, 2, BCBCR.5787.	1.1	6
35	Constitutive activation of p70 S6 kinase is associated with intrinsic resistance to cisplatin. International Journal of Oncology, 2008, 32, 1133-7.	3.3	13
36	Protein kinase C μ makes the life and death decision. Cellular Signalling, 2007, 19, 1633-1642.	3.6	146

#	ARTICLE	IF	CITATIONS
37	Protein kinase C- μ protects MCF-7 cells from TNF-mediated cell death by inhibiting Bax translocation. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 1893-1900.	4.9	35
38	Protein Kinase C μ Activates Protein Kinase B/Akt via DNA-PK to Protect against Tumor Necrosis Factor- α -induced Cell Death. Journal of Biological Chemistry, 2006, 281, 22799-22807.	3.4	83
39	Involvement of proteolytic activation of PKC δ in cisplatin-induced apoptosis in human small cell lung cancer H69 cells. International Journal of Oncology, 2005, 27, 149.	3.3	6
40	Enhancement of Cisplatin Sensitivity of Cisplatin-Resistant Human Cervical Carcinoma Cells by Bryostatin 1. Clinical Cancer Research, 2005, 11, 6730-6737.	7.0	36
41	Activation of ERK during DNA damage-induced apoptosis involves protein kinase C γ . Biochemical and Biophysical Research Communications, 2005, 334, 1068-1073.	2.1	75
42	Involvement of proteolytic activation of PKCdelta in cisplatin-induced apoptosis in human small cell lung cancer H69 cells. International Journal of Oncology, 2005, 27, 149-54.	3.3	9
43	Deregulation of PKB influences antiapoptotic signaling by PKC in breast cancer cells. International Journal of Oncology, 2004, 25, 671.	3.3	1
44	Cisplatin resistance is associated with deregulation in protein kinase C δ . Biochemical and Biophysical Research Communications, 2004, 316, 1002-1008.	2.1	17
45	Involvement of protein kinase C- γ in DNA damage-induced apoptosis. Journal of Cellular and Molecular Medicine, 2003, 7, 341-350.	3.6	103
46	Proteolytic Activation of Protein Kinase C- μ by Caspase-mediated Processing and Transduction of Antiapoptotic Signals. Journal of Biological Chemistry, 2002, 277, 41850-41856.	3.4	75
47	Potential of Tumor Necrosis Factor- α -Induced Cell Death by Rottlerin through a Cytochrome-C-Independent Pathway. Experimental Cell Research, 2002, 278, 209-214.	2.6	13
48	Differential regulation of extrinsic and intrinsic cell death pathways by protein kinase C. International Journal of Molecular Medicine, 2002, 10, 541-5.	4.0	13
49	Regulation of p53 stabilization by DNA damage and protein kinase C. Molecular Cancer Therapeutics, 2002, 1, 861-7.	4.1	24
50	Compartmentalized Protein Kinase C Activation in Ovarian Carcinoma Cells. , 2001, 39, 621-631.		0
51	Differential Sensitivity of Breast Cancer Cells to Tumor Necrosis Factor- α : Involvement of Protein Kinase C. Biochemical and Biophysical Research Communications, 2001, 280, 883-891.	2.1	44
52	Overexpression of Protein Kinase C- δ Attenuates Caspase Activation and Tumor Necrosis Factor- α -Induced Cell Death. Biochemical and Biophysical Research Communications, 2000, 279, 103-107.	2.1	36
53	Regulation of Caspase Activation and <i>cis</i> -Diamminedichloroplatinum(II)-Induced Cell Death by Protein Kinase C. Biochemistry, 1999, 38, 4245-4251.	2.5	85
54	The Involvement of Novel Protein Kinase C Isozymes in Influencing Sensitivity of Breast Cancer MCF-7 Cells to Tumor Necrosis Factor- α . Molecular Pharmacology, 1998, 53, 105-111.	2.3	35

#	ARTICLE	IF	CITATIONS
55	Comparison of protein kinase C activity and isoform expression in cisplatin-sensitive and -resistant ovarian carcinoma cells. <i>International Journal of Cancer</i> , 1995, 62, 457-460.	5.1	31
56	Oncogenic transformation alters cisplatin-induced apoptosis in rat embryo fibroblasts. <i>International Journal of Cancer</i> , 1995, 63, 597-603.	5.1	34
57	Comparison of effects of growth factors and protein kinase C activators on cellular sensitivity to cis-diamminedichloroplatinum(II). <i>International Journal of Cancer</i> , 1994, 58, 587-591.	5.1	18
58	The potential of protein kinase C as a target for anticancer treatment. , 1993, 59, 257-280.		193
59	Synthesis, molecular modeling, 2-D NMR, and biological evaluation of ILV mimics as potential modulators of protein kinase C. <i>Journal of the American Chemical Society</i> , 1993, 115, 3957-3965.	13.7	38
60	Structural requirements of lyngbyatoxin A for activation and downregulation of protein kinase C. <i>Biochemistry</i> , 1992, 31, 3824-3830.	2.5	24
61	Synthesis of structural analogs of lyngbyatoxin A and their evaluation as activators of protein kinase C. <i>Journal of Medicinal Chemistry</i> , 1991, 34, 2420-2430.	6.4	53
62	A hypothesis regarding the protective role of metallothioneins against the toxicity of DNA interactive anticancer drugs. <i>Toxicology Letters</i> , 1990, 50, 123-135.	0.8	71
63	Synthesis and biological studies of simplified analogs of lyngbyatoxin A; use of an isoxazoline-based indole synthesis. Quest for protein kinase C modulators. <i>Journal of the American Chemical Society</i> , 1989, 111, 6228-6234.	13.7	64
64	Mammalian Glucocerebrosidase: Implications for Gaucher's Disease. , 1989, , 3-23.		12
65	Activation of human spleen glucocerebrosidases by monoacylglycerol sulfates and diacylglycerol sulfates. <i>Archives of Biochemistry and Biophysics</i> , 1988, 262, 345-353.	3.0	4
66	Isolation and characterization of a fatty acyl esterase from rat lung. <i>Archives of Biochemistry and Biophysics</i> , 1988, 261, 384-393.	3.0	6
67	Serum lysosomal hydrolases in cystic fibrosis. <i>Clinica Chimica Acta</i> , 1988, 175, 1-9.	1.1	2
68	Comparison of the Acidic Lipid Requirement of Control and Type 1 Gaucher's Disease Liver and Brain Glucocerebrosidases. , 1988, , 73-82.		0
69	Partial Purification and Characterization of Naegleria fowleri ² -Glucosidase1. <i>Journal of Protozoology</i> , 1987, 34, 68-74.	0.8	9
70	Comparison of the ability of phospholipids from rat liver lysosomes to reconstitute glucocerebrosidase. <i>Archives of Biochemistry and Biophysics</i> , 1986, 245, 464-469.	3.0	12
71	Sulfogalactocerebroside and bis-(monoacylglycerol)-phosphate as activators of spleen glucocerebrosidase. <i>Clinica Chimica Acta</i> , 1986, 156, 179-189.	1.1	8
72	Further studies on the activation of glucocerebrosidase by a heat-stable factor from Gaucher spleen. <i>Archives of Biochemistry and Biophysics</i> , 1985, 236, 98-109.	3.0	34

#	ARTICLE	IF	CITATIONS
73	Comparison of N-acyl phosphatidylethanolamines with different N-acyl groups as activators of glucocerebrosidase in various forms of Gaucher's disease. Archives of Biochemistry and Biophysics, 1985, 243, 28-34.	3.0	26
74	Constitutive activation of p70 S6 kinase is associated with intrinsic resistance to cisplatin. International Journal of Oncology, 0, , .	3.3	10